Viewing Study NCT05386550


Ignite Creation Date: 2025-12-24 @ 4:56 PM
Ignite Modification Date: 2026-01-04 @ 3:52 PM
Study NCT ID: NCT05386550
Status: TERMINATED
Last Update Posted: 2025-06-13
First Post: 2022-05-17
Is NOT Gene Therapy: True
Has Adverse Events: False

Brief Title: Phase III Xevinapant (Debio 1143) and Radiotherapy in Resected LA SCCHN, High Risk, Cisplatin-ineligible Participants (XRAY VISION)
Sponsor: EMD Serono Research & Development Institute, Inc.
Organization:

Study Modules

Identification Module Status Module Sponsor Collaborators Module Oversight Module Description Module Conditions Module Design Module Arms Interventions Module Outcomes Module Eligibility Module Contacts Locations Module References Module